Portfolio company AdvanCell Isotopes closed an oversubscribed $315M Series D to advance its Lead-212 PSMA prostate cancer therapy toward Phase 3.
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies for cancer treatment
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies for cancer treatment.